PRME | Prime Medicine, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.9000 - 3.19
52 Week Range	2.9000 - 9.86
Beta	0.64
Implied Volatility	142.33%
IV Rank	36.48%
Day's Volume	1,144,404
Average Volume	1,526,979
Shares Outstanding	131,160,846
Market Cap	392,170,930
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-10-20

Valuation
Profitability
Growth
Health
P/E Ratio	-1.45
Forward P/E Ratio	N/A
EPS	-2.06
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	234
Country	USA
Website	PRME

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

PRME's peers: ALLO, BEAM, CRBU, EDIT, FATE, NTLA, QSI, RPRX, UBX, VERV, SANA, RPHM, DNA, OCEA, CRSP, THRX, LIFE, RLAY, IPSC, BPMC

*Chart delayed

Analyzing fundamentals for PRME we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see PRME Fundamentals page.

Watching at PRME technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PRME Technicals page.